Piper Jaffray Downgrades Thoratec To Neutral

Analysts at Piper Jaffray downgraded Thoratec

from Overweight to Neutral. The target price for Thoratec has been lowered from $40 to $27. Thoratec shares have dropped 33.19% over the past 52 weeks, while the S&P 500 index has gained 20.02% in the same period. Thoratec's shares declined 3.16% to $23.59 in pre-market trading.